利用18F-FDG PET异质性分析表征神经纤维瘤病1型中的恶性外周神经鞘瘤
本研究纳入54例神经纤维瘤病1型(NF1)并临床怀疑神经纤维瘤恶变为恶性外周神经鞘瘤(MPNST)的患者,在注射后1.5小时和4小时行18F-FDG PET,计算六项一阶、四项二阶和四项高阶统计特征,以组织学验证或至少5年临床随访为参考标准将肿瘤分为良性30例和恶性24例。结果显示良恶性肿瘤在全部六项一阶参数、二阶熵(仅4小时)及多数高阶特征上差异显著,但没有任何异质性特征在鉴别良恶性上优于SUVmax。
要点
- 良恶性肿瘤在全部六项一阶参数(1.5小时和4小时)上差异显著,p<0.0001。
- 二阶熵仅在4小时差异显著,高阶特征除4小时对比度外均差异显著。
- 没有任何一阶、二阶或高阶特征在鉴别良恶性上优于SUVmax。
核心结论
- MPNST的18F-FDG摄取高于良性症状性神经纤维瘤(以SUV参数定义),且异质性更高(以一阶和高阶异质性参数定义),但异质性分析并未改善SUVmax的鉴别性能。
研究设计与样本
- 纳入54例神经纤维瘤病1型患者(24例女性,30例男性,平均年龄35.1岁),临床怀疑神经纤维瘤恶变为MPNST。
- 18F-FDG PET按标准临床方案在注射后1.5小时和4小时采集。
- 从肿瘤感兴趣体积中计算六项一阶(包括三项标准化摄取值参数)、四项二阶(基于灰度共生矩阵)和四项高阶(基于邻域灰度差矩阵)统计特征。
- 以组织学验证或至少5年临床随访为参考标准,将肿瘤分为良性30例和恶性24例。
主要发现
- 良性与恶性肿瘤在全部六项一阶参数(1.5小时和4小时)上差异显著,p<0.0001。
- 二阶熵仅在4小时差异显著,高阶特征在1.5小时和4小时(除4小时对比度外)差异显著,p<0.0001-0.047。
- 受试者工作特征曲线下面积对上述相同特征以及1.5小时二阶熵较高(0.669-0.997,p<0.05)。
- 没有任何一阶、二阶或高阶特征在鉴别良恶性肿瘤上优于最大标准化摄取值(SUVmax)。
关键数值与推荐
- 良性肿瘤30例,恶性肿瘤24例,以组织学验证或至少5年临床随访为参考标准。
- 全部六项一阶参数在1.5小时和4小时良恶性差异显著,p<0.0001。
- 受试者工作特征曲线下面积0.669-0.997,p<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Measurement of heterogeneity in 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of 18F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). METHODS: 18F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). RESULTS: There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001-0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669-0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. CONCLUSIONS: 18F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance.
引用
- Cook GJR, Lovat E, Siddique M, et al. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2017. PMID: 28589254. doi:10.1007/s00259-017-3733-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。